Conversely, CBR3-AS1 was upregulated in the non-DMR group, thereby reinforcing their conclusion that CBR3-AS1 overexpression correlates with BCR::ABL1-independent TKI resistance in CML patients. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.